The American Society of Clinical Oncology and Friends of Cancer Research jointly issued recommendations to broaden eligibility criteria in cancer clinical trials, with the goal of making clinical trials more accessible to patients.
In two back-to-back, all-day meetings, the FDA Oncologic Drugs Advisory Committee considered four thorny applications that the agency appeared to have been saving up as a result of the pause in activity that followed President Trump’s return to office.
